Results 71 to 80 of about 45,138 (251)

Focal Segmental Glomerulosclerosis: A Single Center Experience

, 2016
Aim: Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerulonephritis (GNP) worldwide. Despite treatment, it may progress to end-stage renal disease. In the present study, we compared clinical and histopathological data on FSGS with
Ocak, Tuğba, Şahin, Ahmet Bilgehan, Demirayak, Dilay, Gökhan Ocakoğlu, Korkut, Bayram, Mustafa Akan, Can, Fatma Ezgi, Hakan Düger, Bayrakçı, İsmail, Yavuz Ayar, Akan, Mustafa, Bayram Korkut, Eda Eylemer, Ersoy, Alparslan, Oruç, Ayşegül, Yıldız, Abdülmecit, Güllülü, Mustafa, Tuğba Ocak, Ayşegül Oruç, İsmail Bayrakçı, Ayar, Yavuz, Ahmet Bilgehan Şahin, Eylemer, Eda, Mustafa Güllülü, Fatma Ezgi Can, Alparslan Ersoy, Ocakoğlu, Gökhan, Düger, Hakan, Abdülmecit Yıldız, Dilay Demirayak   +29 more
core   +1 more source

A case of minimal change nephrotic syndrome with immunoglobulin A nephropathy transitioned to focal segmental glomerulosclerosis [PDF]

, 2012
A 50-year-old woman with a 1-month history of lower extremity edema and a 5 kg weight increase was admitted to our hospital with suspected nephrotic syndrome in October 1999.
Miyazaki, Masanobu, Takashi Taguchi, Mineaki Kitamura, Misaki Hirose, Obata, Yoko, Uramatsu, Tadashi, Kitamura, Mineaki, Taguchi, Takashi, Nishino, Tomoya, Hirose, Misaki, Tayo Kawazu, Kohno, Shigeru, Shigeru Kohno, Tomoya Nishino, Masanobu Miyazaki, Tadashi Uramatsu, Yoko Obata, Kawazu, Tayo   +17 more
core   +1 more source

PPAR-α Insufficiency Enhances Doxorubicin-Induced Nephropathy in PPAR-α Knockout Mice and a Murine Podocyte Cell Line

Cells
Peroxisome proliferator-activated receptor-alpha (PPAR-α) and its exogenous activators (fibrates) promote autophagy. However, whether the deleterious effects of PPAR-α deficiency on doxorubicin (DOX)-induced podocytopathy are associated with reduced ...
Kohei Matsuta, Kazuko Kamiyama, Toru Imamoto, Izumi Takeda, Shinya Masunaga, Mamiko Kobayashi, Naoki Takahashi, Kenji Kasuno, Masanori Hara, Masayuki Iwano, Tadashi Toyama, Hideki Kimura   +11 more
doaj   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

PLIN5 Protects Against Ang II‐Induced Podocyte Lipotoxicity by Interacting With FKBP8 and Preserving Lipid Droplet–Mitochondria Contact

Cell Proliferation, EarlyView.
PLIN5‐FKBP8 tethers lipid droplets to mitochondria to counteract Ang II‐induced lipotoxicity. ABSTRACT Chronic kidney disease (CKD) remains a major global health challenge. Angiotensin II (Ang II)‐induced lipotoxicity is an important contributor to podocyte injury.
Ping Wang, Wenjie Chen, Jingjing Ke, Hongtu Hu, Zhuan Peng, Yue Qi, Guohua Ding, Jijia Hu   +7 more
wiley   +1 more source

Idiopathic Nodular Glomerulosclerosis: A Case Report

, 2012
Nodular glomerulosclerosis, although once identified as a histopathological diagnosis identical with diabetes mellitus (DM), can be seen in many diseases like membranoproliferative glomerulonephritis, amyloidosis, fibrillary and immunotactoid ...
Rumeyza Kazancioglu, Aydin, Zeki, Tatli, Emel, Ozturk, Savaş, Isın Kılıcaslan, KAZANCIOĞLU, Rümeyza, Serhat Karadag, Gursu, Meltem, Uzun, Sami, Abdullah Sumnu, Meltem Gursu, Sami Uzun, Sumnu, Abdullah, Savas Ozturk, Karadag, Serhat, Emel Tatli, Kiliçaslan, Işin, KILIÇASLAN, Işın, Zeki Aydin   +18 more
core   +1 more source

The insulin‐like growth factor system and the progression of renal complications of type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Chronic kidney disease is associated with dysregulation of the insulin‐like growth factor (IGF) system. Alterations in IGF bioavailability, driven by IGF binding proteins (IGFBPs), may influence the decline in renal function. However, the longitudinal relationship between baseline IGF‐I, IGF‐II, IGFBPs and progression of kidney ...
Adrian Heald, Yasitha lllangasekera, Andreas Matheou, Ram Prakash Narayanan, Stephen White, Hellena Habte‐Asres, Abigail Lay, Liliana Shalamanova, William Ollier, Graham A. Hitman, Ritwika Mallik, Philip A. Kalra, Martin Whyte, J. Martin Gibson   +13 more
wiley   +1 more source

The role of sex and ethnicity in the variability of estimated glomerular filtration rate (eGFR) in people with type 1 diabetes

Diabetic Medicine, EarlyView.
Exploring Sex and Ethnicity Differences in eGFR for People with Type I Diabetes. Abstract Aims To examine sex‐based differences in estimated glomerular filtration rate (eGFR) trajectories for people with type 1 diabetes (T1D) over 10 years and to test the hypothesis that sex and ethnicity interaction predicts eGFR decline.
Salma Ayis, Murat Ozdede, Luigi Gnudi, Thamer Alobaid, Panagiotis Pavlou, Anastasios Mangelis, Nikolaos Fountoulakis, Aicha Goubar, Janaka Karalliedde   +8 more
wiley   +1 more source

Primary focal segmental glomerulosclerosis

, 2018
The proportion of cases of primary focal segmental glomerulosclerosis responsive to treatment with corticosteroids is variable and depends on histological type, patient age and duration, and dose of steroid treatment, but overall complete remission rate ...
Alain Meyrier, Patrick Niaudet
core   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source